<DOC>
	<DOC>NCT00518986</DOC>
	<brief_summary>The primary objective of the study is to evaluate whether armodafinil at a target dosage of 200 mg/day is more effective than placebo treatment in improving excessive sleepiness in patients with obstructive sleep apnea/hypopnea syndrome (OSAHS) who have comorbid major depressive disorder or dysthymic disorder.</brief_summary>
	<brief_title>Efficacy and Safety of Armodafinil for Adults With Excessive Sleepiness Obstructive Sleep Apnea/Hypopnea and Depression</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Apnea</mesh_term>
	<mesh_term>Sleep Apnea Syndromes</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder, Major</mesh_term>
	<mesh_term>Sleep Apnea, Obstructive</mesh_term>
	<mesh_term>Sleep Wake Disorders</mesh_term>
	<mesh_term>Parasomnias</mesh_term>
	<mesh_term>Disorders of Excessive Somnolence</mesh_term>
	<mesh_term>Dysthymic Disorder</mesh_term>
	<mesh_term>Armodafinil</mesh_term>
	<mesh_term>Modafinil</mesh_term>
	<criteria>Current diagnosis of obstructive sleep apnea/hypopnea syndrome (OSAHS) Complaint of residual excessive sleepiness despite nasal continuous positive airway pressure (nCPAP) therapy being effective Current or prior diagnosis of major depressive disorder or dysthymic disorder Clinically stable with regard to depressed mood and has shown a treatment response to selective serotonin reuptake inhibitor (SSRI) therapy or serotonin and norepinephrine reuptake inhibitor (SNRI) therapy Patient has been on a stable monotherapy dose of an allowed SSRI or SNRI for at least 8 weeks at the time of screening Women of childbearing potential must use a medically accepted method of contraception. Confirmed or suspected diagnosis of a currently active sleep disorder other than obstructive sleep apnea/hypopnea syndrome (OSAHS) Current episode of major depression that is considered to be treatmentresistant A primary diagnosis of: eating disorder, psychotic disorder, delirium, dementia, substancerelated disorders, or moderate to severe hypochondriasis Patient has a history of bipolar disorder, psychotic depression, schizophrenia, schizoaffective disorder, any other psychotic disorder, or other clinically significant uncontrolled psychiatric condition. Patient has a history of homicidal ideation or significant aggression Patient has a diagnosis of severe antisocial or borderline personality disorder Has a history of significant suicidal ideation, or has current active suicidal ideation, or is considered at imminent risk of self harm. Patient has a history consistent with fibromyalgia or chronic fatigue syndrome A high consumption of caffeinated products, approximately equivalent to 5 or more cups of coffee per day Patient history of any clinically significant cutaneous drug reaction, or a history of clinically significant hypersensitivity reaction Has a past or present seizure disorder Patient has a history of alcohol, narcotic, or any other substance abuse or dependence (with the exception of nicotine) Psychotherapeutic intervention for the patient was initiated within 8 weeks of the screening visit. Patient has known human immunodeficiency virus (HIV) Patient has any clinically significant uncontrolled medical condition (including illnesses related to the cardiovascular, renal, or hepatic systems) or surgical condition (treated or untreated) Patient is a pregnant or lactating woman Patient has previously received armodafinil; or, patient has used modafinil or any investigational product within 28 days of the baseline visit.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>Obstructive Sleep Apnea/Hypopnea Syndrome</keyword>
	<keyword>Excessive Sleepiness</keyword>
</DOC>